Annals of the American Thoracic Society

Andrea S. Melani, Sara Croce, Gaia Fabbri, Maddalena Messina, Elena Bargagli. (2024) Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History. Biomolecules 14:2, 195.
Online publication date: 6-Feb-2024.
Crossref
Yun-Tai Chen, Pei-Hsin Chen, Fang-Yu Chou, Sheng-Hao Lin, Sung-Yen Huang, Ming-Chung Lee, Yu-Jun Chang, Po-Chi Hsu, Lun-Chien Lo. (2024) The safety and efficacy of Chinese herbal medicine for pneumonia prevention in high-risk elder residents in the nursing home: A randomized, double-blind clinical trial. Journal of Ethnopharmacology 318, 117017.
Online publication date: 1-Jan-2024.
Crossref
David Price, William Henley, José Cançado, Leonardo Fabbri, Huib Kerstjens, Alberto Papi, Nicolas Roche, Elif Şen, Dave Singh, Claus Vogelmeier, Elena Nudo, Victoria Carter, Derek Skinner, Rebecca Vella, Joan Soriano, Maxim Kots, George Georges. (2024) Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS. Pragmatic and Observational Research Volume 15, 1-16.
Online publication date: 1-Jan-2024.
Crossref
Yanxin Wei, Xuefang Liu, Yuhang Jiang, Qingzhou Guan, Yange Tian, Jiansheng Li, Peng Zhao. (2023) Maintenance of airway epithelial barrier integrity via the inhibition of AHR/EGFR activation ameliorates chronic obstructive pulmonary disease using effective-component combination. Phytomedicine 118, 154980.
Online publication date: 1-Sep-2023.
Crossref
Anamarie Tomaich, Shawnee Klatt, Michael W. Nagy. (2023) Narrative Literature Review Guided Approach of Inhaled Corticosteroid de-escalation in Chronic Obstructive Pulmonary Disease. Journal of Pharmacy Practice 36:3, 628-639.
Online publication date: 26-Oct-2021.
Crossref
Hanaa Shafiek. 2023. Inhaled Corticosteroids: Benefits and Risks. Updates on Corticosteroids [Working Title].
Crossref
Christian Rønn, Pradeesh Sivapalan, Josefin Eklöf, Peter Kamstrup, Tor Biering-Sørensen, Barbara Bonnesen, Zitta Barrella Harboe, Andrea Browatzki, Jakob Lyngby Kjærgaard, Christian Niels Meyer, Torben Tranborg Jensen, Sofie Lock Johansson, Elisabeth Bendstrup, Charlotte Suppli Ulrik, Jens-Ulrik Stæhr Jensen. (2023) Hospitalization for chronic obstructive pulmonary disease and pneumonia: association with the dose of inhaled corticosteroids. A nation-wide cohort study of 52 100 outpatients. Clinical Microbiology and Infection 29:4, 523-529.
Online publication date: 1-Apr-2023.
Crossref
Keiji Oishi, Kazuto Matsunaga, Tasuku Yamamoto, Kazuki Matsuda, Yoriyuki Murata, Tsunahiko Hirano. (2023) Practical Recommendations for a Selection of Inhaled Corticosteroids in COPD: A Composite ICO Chart. Biomolecules 13:2, 213.
Online publication date: 22-Jan-2023.
Crossref
Ha Thi Chu, Thuy Chau Nguyen, Isabelle Godin, Olivier Michel. (2023) A Proposal to Differentiate ACO, Asthma and COPD in Vietnam. Journal of Personalized Medicine 13:1, 78.
Online publication date: 29-Dec-2022.
Crossref
Ricardo G. Figueiredo, Lucas F. Araujo, José de Bessa Junior. (2022) The Role of Dual Bronchodilation and the Conscientious Use of Inhaled Corticosteroid in COPD. Sinusitis 6:2, 32-35.
Online publication date: 5-Aug-2022.
Crossref
Sun Hye Shin, Sung Ok Kwon, Victor Kim, Edwin Kepner Silverman, Tae-Hyung Kim, Deog Kyeom Kim, Yong Il Hwang, Kwang Ha Yoo, Woo Jin Kim, Hye Yun Park. (2022) Association of body mass index and COPD exacerbation among patients with chronic bronchitis. Respiratory Research 23:1.
Online publication date: 7-Mar-2022.
Crossref
Ant..nio Duarte-de-Ara..jo, Pedro Teixeira, Venceslau Hespanhol, Jaime Correia-de-Sousa. (2022) COPD: How can evidence from randomised controlled trials apply to patients treated in everyday clinical practice?. Pulmonology 28:6, 431-439.
Online publication date: 1-Nov-2022.
Crossref
Hyunji Jo, Sojung Park, Nam Eun Kim, So Young Park, Yon Ju Ryu, Jung Hyun Chang, Jin Hwa Lee. (2022) Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Clinical Medicine 11:9, 2391.
Online publication date: 24-Apr-2022.
Crossref
Piotr Damiański, Grzegorz Kardas, Michał Panek, Piotr Kuna, Maciej Kupczyk. (2022) Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions. Expert Opinion on Drug Safety 21:4, 499-515.
Online publication date: 26-Nov-2021.
Crossref
Mario Cazzola, Paola Rogliani, Rossella Laitano, Luigino Calzetta, Maria Gabriella Matera. (2022) Beyond Dual Bronchodilation – Triple Therapy, When and Why. International Journal of Chronic Obstructive Pulmonary Disease Volume 17, 165-180.
Online publication date: 1-Jan-2022.
Crossref
Robert A. Wise, Mona Bafadhel, Courtney Crim, Gerard J. Criner, Nicola C. Day, David M.G. Halpin, MeiLan K. Han, Peter Lange, David A. Lipson, Fernando J. Martinez, Diego J. Maselli, Dawn Midwinter, Dave Singh, Maeva Zysman, Mark T. Dransfield, Richard E.K. Russell. (2021) Discordant diagnostic criteria for pneumonia in COPD trials: a review. European Respiratory Review 30:162, 210124.
Online publication date: 17-Nov-2021.
Crossref
Akira Koarai, Mitsuhiro Yamada, Tomohiro Ichikawa, Naoya Fujino, Tomotaka Kawayama, Hisatoshi Sugiura. (2021) Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. Respiratory Research 22:1.
Online publication date: 22-Jun-2021.
Crossref
Mònica Monteagudo, Miriam Barrecheguren, Iryna Solntseva, Nafeesa Dhalwani, Alison Booth, Alexa Nuñez, Dimitra Lambrelli, Marc Miravitlles. (2021) Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD. npj Primary Care Respiratory Medicine 31:1.
Online publication date: 22-Mar-2021.
Crossref
Nicolas Roche, Philippe Devillier, Patrick Berger, Arnaud Bourdin, Daniel Dusser, Jean-François Muir, Yan Martinat, Philippe Terrioux, Bruno Housset. (2021) Individual trajectory-based care for COPD: getting closer, but not there yet. ERJ Open Research 7:4, 00451-2021.
Online publication date: 28-Oct-2021.
Crossref
Holly R. Keir, Marco Contoli, James D. Chalmers. (2021) Inhaled Corticosteroids and the Lung Microbiome in COPD. Biomedicines 9:10, 1312.
Online publication date: 24-Sep-2021.
Crossref
Mario Cazzola, Maria Gabriella Matera. (2021) An Obvious Paradigm. Chest 160:4, 1157-1159.
Online publication date: 1-Oct-2021.
Crossref
Dave Singh. (2021) Pharmacological treatment of stable chronic obstructive pulmonary disease. Respirology 26:7, 643-651.
Online publication date: 7-Apr-2021.
Crossref
Marc Miravitlles, Ariadna Auladell-Rispau, Mònica Monteagudo, Juan Carlos Vázquez-Niebla, Jibril Mohammed, Alexa Nuñez, Gerard Urrútia. (2021) Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. European Respiratory Review 30:160, 210075.
Online publication date: 23-Jun-2021.
Crossref
David M. G. Halpin, Gerard J. Criner, Mark T. Dransfield, MeiLan K. Han, Benjamin Hartley, Catherine Harvey, C. Elaine Jones, Motokazu Kato, Peter Lange, Sally Lettis, David A. Lomas, Fernando J. Martinez, Neil Martin, Dave Singh, Robert Wise, Jinping Zheng, David A. Lipson. (2021) Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulmonary Therapy 7:1, 101-118.
Online publication date: 17-Nov-2020.
Crossref
. (2021) Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. Annals of the American Thoracic Society 18:5, 788-798.
Online publication date: 30-Apr-2021.
Abstract | Full Text | PDF (880 KB) | Supplemental Material 
Beatrice Ludovica Ritondo, Ermanno Puxeddu, Luigino Calzetta, Mario Cazzola, Paola Rogliani. (2021) Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert Opinion on Pharmacotherapy 22:5, 611-620.
Online publication date: 11-Nov-2020.
Crossref
Marco Contoli, Luca Morandi, Fabiano Di Marco, Mauro Carone. (2021) A perspective for chronic obstructive pulmonary disease (COPD) management: six key clinical questions to improve disease treatment. Expert Opinion on Pharmacotherapy 22:4, 427-437.
Online publication date: 6-Oct-2020.
Crossref
Melissa H. Roberts, Gary T. Ferguson. (2021) Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions. PharmacoEconomics - Open 5:1, 3-11.
Online publication date: 18-Jun-2020.
Crossref
Jinping Zheng, Nanshan Zhong, Changzheng Wang, Li Ping Wei, Xiang Dong Zhou, Li Zhao, Ya Dong Yuan, Bei He, Bin Wu, Xin Du, Jie Song, David A. Lipson. (2021) Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial. Current Medical Research and Opinion 37:1, 145-155.
Online publication date: 7-Dec-2020.
Crossref
Leah B Sansbury, Robert P Wood, Glenn A Anley, Yein Nam, Afisi S Ismaila. (2021) Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England. International Journal of Chronic Obstructive Pulmonary Disease Volume 16, 2795-2808.
Online publication date: 1-Oct-2021.
Crossref
Benjamin F. Hartley, Neil C. Barnes, Sally Lettis, Chris H. Compton, Alberto Papi, Paul Jones. (2020) Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. Respiratory Research 21:1.
Online publication date: 6-Jan-2020.
Crossref
Gary T. Ferguson, Nicola Brown, Chris Compton, Thomas C. Corbridge, Kelly Dorais, Charles Fogarty, Catherine Harvey, Morrys C. Kaisermann, David A. Lipson, Neil Martin, Frank Sciurba, Marjorie Stiegler, Chang-Qing Zhu, David Bernstein. (2020) Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respiratory Research 21:1.
Online publication date: 29-May-2020.
Crossref
Takudzwa Mkorombindo, Mark T. Dransfield. (2020) Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 41:3, 475-484.
Online publication date: 1-Sep-2020.
Crossref
Luigino Calzetta, Maria Gabriella Matera, Paola Rogliani, Mario Cazzola. (2020) The role of triple therapy in the management of COPD. Expert Review of Clinical Pharmacology 13:8, 865-874.
Online publication date: 13-Jul-2020.
Crossref
Mahmood A. Al-Azzawi, Mohamed M.N. AboZaid, Reda Abdel Latif Ibrahem, Moustafa A. Sakr. (2020) Therapeutic effects of black seed oil supplementation on chronic obstructive pulmonary disease patients: A randomized controlled double blind clinical trial. Heliyon 6:8, e04711.
Online publication date: 1-Aug-2020.
Crossref
Thomas Keller, Laura J. Spece, Lucas M. Donovan, Edmunds Udris, Scott S. Coggeshall, Matthew Griffith, Alexander D. Bryant, Richard Casaburi, J. Allen Cooper, Gerard J. Criner, Philip T. Diaz, Anne L. Fuhlbrigge, Steven E. Gay, Richard E. Kanner, Fernando J. Martinez, Ralph J. Panos, David Shade, Alice Sternberg, Thomas Stibolt, James K. Stoller, James Tonascia, Robert Wise, Roger D. Yusen, David H. Au, Laura C. Feemster. (2020) Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life. Chest 158:2, 529-538.
Online publication date: 1-Aug-2020.
Crossref
Saibal Moitra, Mrinal Sircar, Nevin Kishore. (2020) Management of Chronic Obstructive Pulmonary Disease: Insights into Patient Profile – Use of Inhaled Corticosteroids/Long-Acting β2-Agonists or Long-Acting β2-Agonists/Long-acting Muscarinic Antagonists. Indian Journal of Respiratory Care 9:2, 162-170.
Online publication date: 8-Dec-2022.
Crossref
Qian Zhang, Shuo Li, Wei Zhou, Xia Yang, Jinna Li, Jie Cao. (2020) Risk of Pneumonia with Different Inhaled Corticosteroids in COPD Patients: A Meta-Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease 17:4, 462-469.
Online publication date: 9-Jul-2020.
Crossref
Dan Mei, W.S. Daniel Tan, Yvonne Tay, Amartya Mukhopadhyay, W.S. Fred Wong. (2020) Therapeutic RNA Strategies for Chronic Obstructive Pulmonary Disease. Trends in Pharmacological Sciences 41:7, 475-486.
Online publication date: 1-Jul-2020.
Crossref
. (2020) Predicting Pneumonia in Chronic Obstructive Pulmonary Disease. Have We Unraveled the Network of Risks?. American Journal of Respiratory and Critical Care Medicine 201:9, 1026-1027.
Online publication date: 1-May-2020.
First Page | Full Text | PDF (508 KB) | Supplemental Material 
Maria Gabriella Matera, , Paola Rogliani, , Luigino Calzetta, , Mario Cazzola, . (2020) Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. US Respiratory & Pulmonary Diseases 5:1, 18.
Online publication date: 1-Jan-2020.
Crossref
Andriana I Papaioannou, Stelios Loukides, Petros Bakakos, Epameinondas N Kosmas, Nikoletta Rovina, Paschalis Steiropoulos, Evangellia Fouka, Georgios Hillas, Georgios Patentalakis, Marousa Kouvela, Nikos Tzanakis. (2020) <p>Dual Bronchodilator in the Era of Triple Therapy</p>. International Journal of Chronic Obstructive Pulmonary Disease Volume 15, 2695-2705.
Online publication date: 1-Oct-2020.
Crossref
Ji-Ho Lee, You Hyun Park, Dae Ryong Kang, Seok Jeong Lee, Myoung Kyu Lee, Sang-Ha Kim, Suk Joong Yong, Won-Yeon Lee. (2020) Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study. International Journal of Chronic Obstructive Pulmonary Disease Volume 15, 3397-3406.
Online publication date: 1-Dec-2020.
Crossref
Bronwyn Boyes. (2019) Building Hope by Restoring Breathing in Airways Diseases. EMJ Respiratory, 32-41.
Online publication date: 14-Nov-2019.
Crossref
Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson, Chen Wang, Dave Singh, Jadwiga A. Wedzicha, Roopa Trivedi, Earl St Rose, Shaila Ballal, Julie McLaren, Patrick Darken, Colin Reisner, Paul Dorinsky. (2019) A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respiratory Medicine 158, 59-66.
Online publication date: 1-Oct-2019.
Crossref
Chin Kook Rhee, Ngo Quy Chau, Faisal Yunus, Kazuto Matsunaga, Diahn‐Warng Perng, . (2019) Management of COPD in Asia: A position statement of the Asian Pacific Society of Respirology. Respirology 24:10, 1018-1025.
Online publication date: 5-Jul-2019.
Crossref
Marie Stolbrink, Laura J Bonnett, John D Blakey. (2019) Antibiotics for COPD exacerbations: does drug or duration matter? A primary care database analysis. BMJ Open Respiratory Research 6:1, e000458.
Online publication date: 17-Sep-2019.
Crossref
S. N. Avdeev, Z. R. Aisanov, V. V. Arkhipov, A. S. Belevskiy, I. V. Leshchenko, S. I. Ovcharenko, E. I. Shmelev, M. Miravitls. (2019) Withdrawal of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Russian Pulmonology 29:3, 334-345.
Online publication date: 17-Aug-2019.
Crossref
Sergey N. Avdeev, Natal’ya V. Trushenko. (2019) Triple therapy in chronic obstructive pulmonary disease. Russian Pulmonology 29:2, 199-206.
Online publication date: 1-Jul-2019.
Crossref
Chitra Lal, Charlie Strange. (2019) Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy 20:9, 1075-1085.
Online publication date: 14-Apr-2019.
Crossref
Jing Huang, Jiquan Guo, Hongtao Li, Weibin Huang, Tiantuo Zhang. (2019) Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia. Medicine 98:13, e14636.
Online publication date: 1-Mar-2019.
Crossref
Kenta Yamamura, Johsuke Hara, Takafumi Kobayashi, Noriyuki Ohkura, Miki Abo, Kyota Akasaki, Syunichi Nomura, Mizuki Yuasa, Keigo Saeki, Nanao Terada, Hiroki Matsuoka, Yuichi Tambo, Shingo Nishikawa, Takashi Sone, Hideharu Kimura, Kazuo Kasahara. (2019) The prevalence and clinical features of asthma-COPD overlap (ACO) definitively diagnosed according to the Japanese Respiratory Society Guidelines for the Management of ACO 2018. The Journal of Medical Investigation 66:1.2, 157-164.
Online publication date: 15-Feb-2019.
Crossref
Nawar Diar Bakerly, Ashley Woodcock, Susan Collier, David A. Leather, John P. New, Jodie Crawford, Catherine Harvey, Jørgen Vestbo, Isabelle Boucot. (2019) Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups. Respiratory Medicine 147, 58-65.
Online publication date: 1-Feb-2019.
Crossref
Cassandra Bailey, Paul J. Wojciechowski, William E. Hurford. 2019. Pharmacology of the Airways. Principles and Practice of Anesthesia for Thoracic Surgery, 151-164.
Crossref
Preyanate Wilairat, Kirati Kengkla, Chaiyawat Thayawiwat, Phongsathorn Phlaisaithong, Supakorn Somboonmee, Surasak Saokaew. (2019) Clinical outcomes of theophylline use as add-on therapy in patients with chronic obstructive pulmonary disease: A propensity score matching analysis. Chronic Respiratory Disease 16, 147997311881569.
Online publication date: 17-Dec-2018.
Crossref
I. V. Leshchenko. (2018) Possibilities and limitations of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease. Russian Pulmonology 28:5, 602-612.
Online publication date: 24-Dec-2018.
Crossref
Alvar Agusti, Leonardo M. Fabbri, Dave Singh, Jørgen Vestbo, Bartolome Celli, Frits M.E. Franssen, Klaus F. Rabe, Alberto Papi. (2018) Inhaled corticosteroids in COPD: friend or foe?. European Respiratory Journal 52:6, 1801219.
Online publication date: 6-Sep-2018.
Crossref
James D. Chalmers, Chris Poole, Samantha Webster, Abigail Tebboth, Scott Dickinson, Alicia Gayle. (2018) Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD). Respiratory Research 19:1.
Online publication date: 11-Apr-2018.
Crossref
, Nicholas P. Williams, Kristoffer Ostridge, Jeanne-Marie Devaster, Viktoriya Kim, Ngaire A. Coombs, Simon Bourne, Stuart C. Clarke, Stephen Harden, Ausami Abbas, Emmanuel Aris, Christophe Lambert, Andrew Tuck, Anthony Williams, Stephen Wootton, Karl J. Staples, Tom M. A. Wilkinson. (2018) Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD. Respiratory Research 19:1.
Online publication date: 28-Jul-2018.
Crossref
Donald P. Tashkin, Marc Miravitlles, Bartolomé R. Celli, Norbert Metzdorf, Achim Mueller, David M. G. Halpin, Antonio Anzueto. (2018) Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. Respiratory Research 19:1.
Online publication date: 5-Oct-2018.
Crossref
Songsong Yu, Qiuhong Fang, Yinjuan Li. (2018) Independent factors associated with pneumonia among hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease. Medicine 97:42, e12844.
Online publication date: 1-Oct-2018.
Crossref
Dave Singh. (2018) Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 19:11, 1279-1287.
Online publication date: 13-Aug-2018.
Crossref
Adrian Gillissen. (2018) Tripletherapie bei schwerer COPD trotz vermehrter Pneumonien erfolgreicher. Pneumo News 10:4, 18-20.
Online publication date: 22-Jun-2018.
Crossref
Maria Gabriella Matera, Luigino Calzetta, Ermanno Puxeddu, Paola Rogliani, Mario Cazzola. (2018) A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17:5, 509-517.
Online publication date: 8-Mar-2018.
Crossref
Dave Singh, Peter J. Barnes, Robert Stockley, Maria Victorina Lopez Valera, Claus Vogelmeier, Alvar Agusti. (2018) Pharmacological treatment of COPD: the devil is always in the detail. European Respiratory Journal 51:4, 1800263.
Online publication date: 19-Apr-2018.
Crossref
Marc Miravitlles, Borja G. Cosío, Aurelio Arnedillo, Myriam Calle, Bernardino Alcázar-Navarrete, Cruz González, Cristóbal Esteban, Juan Antonio Trigueros, José Miguel Rodríguez González-Moro, José Antonio Quintano Jiménez, Adolfo Baloira. (2017) A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respiratory Research 18:1.
Online publication date: 28-Nov-2017.
Crossref
Sara Roversi, Lorenzo Corbetta, Enrico Clini. (2017) GOLD 2017 recommendations for COPD patients: toward a more personalized approach. COPD Research and Practice 3:1.
Online publication date: 5-May-2017.
Crossref
James D. Chalmers, Abigail Tebboth, Alicia Gayle, Andrew Ternouth, Nick Ramscar. (2017) Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. npj Primary Care Respiratory Medicine 27:1.
Online publication date: 29-Jun-2017.
Crossref
Satyadeo Choubey, Babaji Ghewade. (2017) PHARMACOTHERAPY IN COPD- RECENT INNOVATIONS AND RESEARCH. Journal of Evidence Based Medicine and Healthcare 4:91, 5512-5517.
Online publication date: 27-Nov-2017.
Crossref
Timothy H. Self, Samantha Ellingson. (2017) New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler. The American Journal of Medicine 130:11, 1251-1254.
Online publication date: 1-Nov-2017.
Crossref
Courtney Crim, Peter M.A. Calverley, Julie A. Anderson, Andrew P. Holmes, Sally Kilbride, Fernando J. Martinez, Robert D. Brook, David E. Newby, Julie C. Yates, Bartolomé R. Celli, Jørgen Vestbo. (2017) Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. Respiratory Medicine 131, 27-34.
Online publication date: 1-Oct-2017.
Crossref
Frederico Leon Arrabal Fernandes, Alberto Cukier, Aquiles Assunção Camelier, Carlos Cezar Fritscher, Cláudia Henrique da Costa, Eanes Delgado Barros Pereira, Irma Godoy, José Eduardo Delfini Cançado, José Gustavo Romaldini, Jose Miguel Chatkin, José Roberto Jardim, Marcelo Fouad Rabahi, Maria Cecília Nieves Maiorano de Nucci, Maria da Penha Uchoa Sales, Maria Vera Cruz de Oliveira Castellano, Miguel Abidon Aidé, Paulo José Zimermann Teixeira, Renato Maciel, Ricardo de Amorim Corrêa, Roberto Stirbulov, Rodrigo Abensur Athanazio, Rodrigo Russo, Suzana Tanni Minamoto, Fernando Luiz Cavalcanti Lundgren. (2017) Recommendations for the pharmacological treatment of COPD: questions and answers. Jornal Brasileiro de Pneumologia 43:4, 290-301.
Online publication date: 1-Aug-2017.
Crossref
Klaus F Rabe, Henrik Watz. (2017) Chronic obstructive pulmonary disease. The Lancet 389:10082, 1931-1940.
Online publication date: 1-May-2017.
Crossref
Štefan Laššán, Marta Hájková, Monika Laššánová. (2017) Anti-inflammatory treatment of stable COPD - current trends and recommendations for clinical practiceExperts statement. Klinická farmakologie a farmacie 31:1, 22-30.
Online publication date: 1-May-2017.
Crossref
. (2017) Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine 195:7, 881-888.
Online publication date: 31-Mar-2017.
Abstract | Full Text | PDF (648 KB) | Supplemental Material 
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez‐Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha, Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology 22:3, 575-601.
Online publication date: 7-Mar-2017.
Crossref
. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine 195:5, 557-582.
Online publication date: 1-Mar-2017.
Abstract | Full Text | PDF (946 KB) | Supplemental Material 
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha, Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos de Bronconeumología (English Edition) 53:3, 128-149.
Online publication date: 1-Mar-2017.
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martínez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolás Roche, Roberto Rodríguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha, Alvar Agustí. (2017) Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. Archivos de Bronconeumología 53:3, 128-149.
Online publication date: 1-Mar-2017.
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha, Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal 49:3, 1700214.
Online publication date: 30-Jan-2017.
Crossref
Thomas M. Siler, Atsushi Nagai, Catherine A. Scott-Wilson, Dawn A. Midwinter, Courtney Crim. (2017) A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respiratory Medicine 123, 8-17.
Online publication date: 1-Feb-2017.
Crossref
Seong Yong Lim. 2017. Pharmacologic Management. COPD, 219-242.
Crossref
Philip E Silkoff, Dave Singh, J Mark FitzGerald, Andreas Eich, Andrea Ludwig-Sengpiel, Geoffrey C Chupp, Vibeke Backer, Celeste Porsbjerg, Pierre-Olivier Girodet, Mark T Dransfield, Frederic Baribaud, Vedrana S Susulic, Matthew J Loza. (2017) Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. Biomarker Insights 12, 117727191773030.
Online publication date: 7-Sep-2017.
Crossref
Dave Singh. (2017) Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases 80:4, 317.
Online publication date: 1-Jan-2017.
Crossref
(2016) Effectiveness of Fluticasone Furoate–Vilanterol in COPD. New England Journal of Medicine 375:26, 2605-2607.
Online publication date: 29-Dec-2016.
Crossref
T. Chinet, J. Dumoulin, I. Honore, J.-M. Braun, L.-J. Couderc, M. Febvre, G. Mangiapan, C. Maurer, P. Serrier, F. Soyez, P. Terrioux, G. Jebrak. (2016) Place des corticostéroïdes inhalés dans la BPCO. Revue des Maladies Respiratoires 33:10, 877-891.
Online publication date: 1-Dec-2016.
Crossref
M. Zysman, F. Chabot, P. Devillier, B. Housset, C. Morelot-Panzini, N. Roche. (2016) Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Société de Pneumologie de Langue Française. Revue des Maladies Respiratoires 33:10, 911-936.
Online publication date: 1-Dec-2016.
Crossref
Barbara P Yawn, Samy Suissa, Andrea Rossi. (2016) Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. npj Primary Care Respiratory Medicine 26:1.
Online publication date: 29-Sep-2016.
Crossref
Paolo Montuschi, Mario Malerba, Giuseppe Macis, Nadia Mores, Giuseppe Santini. (2016) Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discovery Today 21:11, 1820-1827.
Online publication date: 1-Nov-2016.
Crossref
Nanshan Zhong, Changzheng Wang, Xiangdong Zhou, Nuofu Zhang, Michael Humphries, Linda Wang, Francesco Patalano, Donald Banerji. (2016) Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study. COPD: Journal of Chronic Obstructive Pulmonary Disease 13:6, 686-692.
Online publication date: 11-Aug-2016.
Crossref
. (2016) Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 194:5, 541-549.
Online publication date: 1-Sep-2016.
Abstract | Full Text | PDF (606 KB) | Supplemental Material 
Ian D Pavord, Sally Lettis, Antonio Anzueto, Neil Barnes. (2016) Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. The Lancet Respiratory Medicine 4:9, 731-741.
Online publication date: 1-Sep-2016.
Crossref
Surya P Bhatt. (2016) Eosinophils in COPD: the Janus of phenotyping response to therapy?. The Lancet Respiratory Medicine 4:9, 681-683.
Online publication date: 1-Sep-2016.
Crossref
Steven J. Pascoe, David A. Lipson, Nicholas Locantore, Helen Barnacle, Noushin Brealey, Rajat Mohindra, Mark T. Dransfield, Ian Pavord, Neil Barnes. (2016) A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. European Respiratory Journal 48:2, 320-330.
Online publication date: 13-Jul-2016.
Crossref
Pavlina A. Andreeva-Gateva, Eleonora Stamenova, Tzvetelin Gatev. (2016) The place of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease: a narrative review. Postgraduate Medicine 128:5, 474-484.
Online publication date: 27-May-2016.
Crossref
Mario Malerba, Alessandro Radaeli, Paolo Montuschi, Jaymin B. Morjaria. (2016) Vilanterol trifenatate for the treatment of COPD. Expert Review of Respiratory Medicine 10:7, 719-731.
Online publication date: 25-May-2016.
Crossref
Donald Banerji, Donald A. Mahler, Nicola A. Hanania. (2016) Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. Expert Review of Respiratory Medicine 10:7, 767-780.
Online publication date: 30-May-2016.
Crossref
Hernan Iannella, Carlos Luna, Grant Waterer. (2016) Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated review. Therapeutic Advances in Respiratory Disease 10:3, 235-255.
Online publication date: 18-Feb-2016.
Crossref
Henrik Watz, Kay Tetzlaff, Emiel F M Wouters, Anne Kirsten, Helgo Magnussen, Roberto Rodriguez-Roisin, Claus Vogelmeier, Leonardo M Fabbri, Pascal Chanez, Ronald Dahl, Bernd Disse, Helen Finnigan, Peter M A Calverley. (2016) Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. The Lancet Respiratory Medicine 4:5, 390-398.
Online publication date: 1-May-2016.
Crossref
Peter Calverley, Ben Vlies. (2016) A rational approach to single, dual and triple therapy in COPD. Respirology 21:4, 581-589.
Online publication date: 26-Nov-2015.
Crossref
Jørgen Vestbo, Julie A Anderson, Robert D Brook, Peter M A Calverley, Bartolome R Celli, Courtney Crim, Fernando Martinez, Julie Yates, David E Newby. (2016) Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet 387:10030, 1817-1826.
Online publication date: 1-Apr-2016.
Crossref
Bryony Coupe, Andrew L. Griffiths, Gwyneth A. Davies. 2016. Drugs That Act on the Respiratory Tract. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, 153-164.
Crossref
Rebecca Clarke, Fionnuala T Lundy, Lorcan McGarvey. (2015) Herbal treatment in asthma and COPD – current evidence. Clinical Phytoscience 1:1.
Online publication date: 8-Aug-2015.
Crossref
Peter Calverley. (2015) Knowing when to stop: inhaled corticosteroids and COPD. European Respiratory Journal 46:5, 1236-1238.
Online publication date: 31-Oct-2015.
Crossref
Andrea P. Rossi, Erika Zanardi, Mauro Zamboni, Andrea Rossi. (2015) Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?. Drugs & Aging 32:9, 679-687.
Online publication date: 22-Aug-2015.
Crossref
Anthony D’Urzo, James F Donohue, Peter Kardos, Marc Miravitlles, David Price. (2015) A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 16:12, 1845-1860.
Online publication date: 21-Jul-2015.
Crossref
Adamantia Liapikou, Michael Toumbis, Antoni Torres. (2015) Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia. Expert Opinion on Drug Safety 14:8, 1237-1247.
Online publication date: 25-Jun-2015.
Crossref
Prescott G Woodruff, Alvar Agusti, Nicolas Roche, Dave Singh, Fernando J Martinez. (2015) Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. The Lancet 385:9979, 1789-1798.
Online publication date: 1-May-2015.
Crossref
Jørgen Vestbo, Peter Lange. (2015) Prevention of COPD exacerbations: medications and other controversies. ERJ Open Research 1:1, 00011-2015.
Online publication date: 6-May-2015.
Crossref

Related

No related items
Comments Post a Comment




New User Registration

Not Yet Registered?
Benefits of Registration Include:
 •  A Unique User Profile that will allow you to manage your current subscriptions (including online access)
 •  The ability to create favorites lists down to the article level
 •  The ability to customize email alerts to receive specific notifications about the topics you care most about and special offers
Annals of the American Thoracic Society
12
1

Click to see any corrections or updates and to confirm this is the authentic version of record